Pazopanib vs sunitinib (targeted agent versus targeted agent)
Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
- no estimate extracted1 study · 467 participantsLow